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The CANCER-ID consortium is funded by IMI (Fig. 1). This public-private partnership 
between the EU commission and the European Federation of Pharmaceutical 
Industries and Associations (EFPIA) provides a legal framework for addressing unmet 
challenges in the healthcare sector. 
In 2015, academic and clinical research groups, public research organizations, small 
and medium-sized enterprises (SME), and pharmaceutical and diagnostic 
corporations joined forces to evaluate technologies and establish analytical 
standards in the liquid biopsy field.
The academic leaders of CANCER-ID, Professor Klaus Pantel (UKE, Germany), who has 
published >300 reports and high-impact review articles on disseminating tumor cells, 
and Professor Leon Terstappen (Universiteit Twente, The Netherlands), developer of 
the FDA-approved benchmark CELLSEARCH® CTC detection system, are pioneers in 
the field of blood-based cancer biomarkers.
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The CANCER-ID consortium
Poster presented at the AACR Annual Meeting, March 29 - April 3, 2019, Atlanta, GA, USA
To improve the CTC yield in NSCLC 
patients, new workflows were 
established using Diagnostic 
Leukapheresis (DLA) [3, 4] (Fig. 3). CTC 
detection frequency was significantly 
increased (p=0.03, Friedman’s 2-way 
ANOVA by rank) when measured in a 
DLA product (~ 2 x 108 cells, 1-3 mL of 
DLA product) compared to peripheral 
blood (15 mL) prior to ICI treatment. 
There was a trend towards further 
increase in the CTC detection frequency 
in DLA product (18 mL) when an 
immunodensity-based cell enrichment 
(RosetteSepTM, Stemcell Technologies) 
procedure (p=0.09) was used. After 
treatment, no differences were observed 
in the percentage of patients with CTCs 
detected in peripheral blood or DLA 
product. The cell enrichment by 
RosetteSepTM again increased the yield of 
CTCs in DLA product (p=0.007, 
Friedman’s 2-way ANOVA by rank).
Efforts to improve the CTC yield in NSCLC patients
Figure 2. Comparison of workflows using either diverse input 
samples and protocols or well-defined input samples and 
consensus protocols. 
The CANCER-ID partners are currently jointly analyzing samples from advanced NSCLC and 
metastatic breast cancer patients who are participating in clinical studies at clinical partner 
sites, or are under ICI treatment at clinics (Table 1 and Table 2). The samples will be 
collected at baseline and 1-2 and 4-6 months after treatment initiation (Fig. 4). 
The aim of this study is to investigate whether CTC counts or mutational analysis of ctDNA 
using next-generation sequencing (NGS) panels combined with droplet digital PCR (ddPCR) 
can be used for the selection of patients who may benefit from PD-1/PD-L1 inhibition and 
identify early signs of efficacy or relapse.
This approach is supported by the results obtained from NSCLC patients treated with 
checkpoint inhibitors, a study performed at UMCG (Table 1). 
Improved patient selection for immune checkpoint inhibition (ICI) treatments 
CANCER-ID (www.cancer-id.eu) is a five-year (2015-2019) international public-private 
partnership project supported by Europe’s Innovative Medicines Initiative (IMI). The 
consortium of currently 40 partners from 14 countries (Fig. 1) aims at the 
establishment of harmonized best practice protocols for patient sample collection, 
pre-analytical sample handling, sample and bioinformatic analyses, and actionable 
information guiding patient selection for personalized treatment. 
CANCER-ID tests and supports the development of standards for liquid biopsy as well 
as clinical implementation of liquid biopsy-based protocols in the clinical setting. 
This includes interaction with regulatory bodies, such as EMA’s (European Medicines 
Agency) Innovation Task Force (ITF) and CDER/FDA’s (U.S. Center for Drug Evaluation 
and Research/Food and Drug Administration) Critical Path Innovation Meeting (CPIM), 
to support future approval of liquid biopsies in multi-centered worldwide clinical 
studies. 
At the core of CANCER-ID’s activities in the liquid biopsy field is the evaluation of 
technologies for circulating tumor cell (CTC), circulating tumor DNA (ctDNA), 
microRNA (miRNA) and exosome enrichment, isolation and analysis.
Liquid biopsy protocols are being implemented in an observational study evaluating 
the utility of analyzing PD-L1 (programmed death-ligand 1) expression on CTCs in 
non-small cell lung cancer (NSCLC) and metastatic breast cancer. To this end, the 
potential predictive value of monitoring treatment response towards immune 
checkpoint inhibition (ICI) is assessed in advanced NSCLC patients at the University 
Medical Center Groningen (UMCG) as well as in two ICI-chemotherapy combination 
studies in triple-negative breast cancer and luminal B breast cancer, respectively, run 
by the University of Oslo (ALICE, ClinicalTrials.gov ID: NCT03164993 and ICON, 
ClinicalTrials.gov ID: NCT03409198). 
The aim is to assess whether the allelic frequency of mutations as a potential 
measure for tumor mutational burden (TMB) or the number of PD-L1-positive/overall 
CTCs at different time points is indicative of treatment success. 
As a follow-up activity of the CANCER-ID program, the European Liquid Biopsy Society 
(ELBS) is currently being established. The ELBS will be open to all interested liquid 
biopsy stakeholders worldwide as a platform for scientific exchange.
Figure 1. The CANCER-ID consortium, funded by IMI.   
Standardization of liquid biopsy technologies
The use of diverse input sample types 
(e.g. different blood fixatives, 
extraction protocols or analysis 
technologies) and substantially 
different user-developed protocols 
for blood-based analytes like CTCs, 
ctDNA or miRNA hampers the 
comparability of results (Fig. 2). 
Hence, there is a need to standardize 
liquid biopsy technologies. The 
multicenter ring trials for the 
evaluation of CTC, ctDNA and miRNA 
technologies include the analysis of 
standard materials (e.g. well-defined 
NSCLC spike-in controls, ctDNA 
reference material) by multiple 
CANCER-ID partners following a 
consensus protocol or workflow to 
ensure the comparability of 
results [1, 2].
Figure 3.  Establishing new workflows for improving the CTC yield 
in NSCLC patients using Diagnostic Leukapheresis (DLA). 
(A) Schematic drawing of DLA. (B) The percentage of patients with CTCs 
detected in peripheral blood (PB) prior to and after DLA procedure and 
in DLA product with and without RosetteSepTM enrichment. The 
percentage of NSCLC patients with CTCs was assessed in peripheral 
blood and DLA products before and after treatment with 
standard-of-care chemotherapy, tyrosine kinase inhibitors or ICI using 
CELLSEARCH®. Statistical analyses were performed using Fischer’s 
exact test (n.s., not significant).
A
Figure 4. Sample collection workflow for the project aiming for 
improved stratification of patients for ICI treatments. 












































CANCER-ID is supported by the Innovative Medicines Initiative (IMI) Joint Undertaking under Grant 
Agreement n° 115749, resources of which are composed of financial contribution from the European 
Union’s Seventh Framework Programme (FP7/2007-2013) and EFPIA companies’ in-kind 
contributions.
Samples from patients were collected under signed informed consent.
Aurexel Life Sciences Ltd. (www.aurexel.com) is thanked for editorial assistance in the preparation of 
this poster, funded by Bayer AG.
IMI’s CANCER-ID project ends in December 2019. The requirement for continued data 
and sample storage, further updating of best practice documents and standard 
operating procedures (SOPs) and scientific support of liquid biopsy proficiency testing 
have led to plans for sustained activity in the field by academic and industrial partners. 
The University Medical Center Hamburg-Eppendorf (UKE, Hamburg) is currently 
establishing the “European Liquid Biopsy Society” (ELBS) (Fig. 7) with the following 
goals:
International stakeholders worldwide are cordially invited to join the ELBS and support 
the advancement of liquid biopsy in cancer research and therapy. A kick-off meeting is 
being planned for May 3rd 2019 at UKE in Hamburg, Germany. For additional 
information please contact Prof. Klaus Pantel (pantel@uke.de).
The European Liquid Biopsy Society
Table 1. Characteristics of the ICI study in NSCLC patients.  
Table 2. Characteristics of ALICE and ICON phase IIb breast cancer 
studies.
ALICE, phase IIb, trial NCT03164993 ICON, phase IIb, trial NCT03409198
Randomized, double-blind, placebo-
controlled study evaluating the 
efficacy and safety of atezolizumab
when combined with immunogenic 
chemotherapy* in subjects with 
metastatic TNBC
Randomized study evaluating the 
safety and efficacy of combining 
nivolumab and ipilimumab with 
immunogenic chemotherapy* in 
subjects with metastatic luminal B 
breast cancer








Arm B: Chemo + 
ipilimumab + 
nivolumab
* Chemotherapy: pegylated liposomal doxorubicin + cyclophosphamide
DR, duration of response; DRR, durable tumor response rate; ORR, overall tumor response rate; OS, overall survival
Total of 75 patients randomized 2:3 Total of 75 patients randomized 2:3 in 
favour of arm B, stratified according to 
tumor PD-L1 status
Primary objectives: assessment of clinical response (PFS) and toxicity of 
combined treatment
Secondary objectives (among others): assessment of clinical response (ORR, DR, 
DRR > 6 months, OS) and identification of biomarkers for clinical response, 
toxicity and immune response
Figure 7. Scope of the European Liquid Biopsy Society (ELBS).  
B
Figure 5. The percentage of early and durable responders in NSCLC 
patients treated with ICIs, stratified for CTC presence at baseline 
and CTC change after therapy. The bars represent the percentage of 
patients (n = 104 before treatment, n = 63 after treatment) with or 
without circulating tumor cells (CTC) at baseline or with increased or 
stable CTC counts (∆CTC) at four to six weeks of therapy compared to 
baseline. CELLSEARCH® analysis was performed using 7.5 mL of blood 
and a corresponding volume of DLA product based on the white blood 
cell count. Statistical analyses were performed using Fischer’s exact 














































































































In this study, CTC presence at baseline and CTC change after therapy was used as a 
stratification tool, and the percentage of early responders (partial and complete response 
according to RECIST 1.1) and durable responders (stable disease, partial response and 
complete response according to RECIST 1.1 without progression in 6 months) to ICIs was 
determined. 
Early response rates were not significantly different (T0: odds ratio, OR=0.67, p=0.56; ∆CTC 
OR=0.13, p=0.08), whereas, the durable response rate was significantly decreased in patients 
with CTCs (T0: OR=0.28, p=0.02; ∆CTC OR=0.04, p<0.01) (Fig. 5). 
Preliminary data show that a decline in the ctDNA mutation variant allele frequency (VAF) 


























Patients with increased 
or stable CTC counts
Patients with decreased 






Foster the introduction of liquid biopsy into clinical practice.
Encourage interactions between academia and industry as well as other related 
initiatives (e.g. The US-based Blood Profiling Atlas in Cancer, BloodPAC; FNIH).
Provide a partner for regulatory agencies, healthcare providers and patient 
advocacy groups.
Support the implementation of liquid biopsy tests into clinical trials.
Develop guidelines and provide training in liquid biopsy for medical scientists.
Disseminate knowledge about liquid biopsies to the medical community through 
regular symposia, publications and press releases.
Figure 6. Decline in ctDNA mutation variant allele frequency (VAF) predicts progression-free survival (PFS) and 
overall survival (OS). (A) Preliminary analysis indicates that stabilization or decline in VAF of NGS-identifed mutations 
in ICI-treated patients is predictive of partial response or stable disease under treatment. (B) Rising VAFs are predictive 
of progressive disease. The AVENIO Expanded ctDNA NGS Analysis Kit (Roche), a pan-cancer NGS panel with 77 genes, 
was used to identify mutations in advanced NSCLC patients at baseline and approximately 4 weeks into treatment. 
From 7.5 mL of blood an average of 10 ng of circulating-free DNA was extracted and mutations from multiple tumor 



























































Tumor response: PR; no event (progression or 
death) after 450 d. 
Tumor response: CR; no event (progression 
or death) after 576 d. 
Tumor response: PR after ipi/nivo; PFS: 
245 d; OS: alive after 289 d. 
Tumor response: PD; PFS: 8 d; OS: 59 d. Tumor response: PD; PFS: 45 d; OS: 53 d. Tumor response: PD; PFS: 43 d; OS: 405 d. 
112 patients documented – median age 65 yrs (range 29-83 yrs)
Outcome in tumor response measured with RECIST v1.1, progression-free survival 
(PFS) and overall survival (OS) is well-documented
Corresponding data on CTCs and tumor-derived extracellular vesicles (tdEV) 
is available
Paired analysis of 180 NSCLC patients 
(UMCG Groningen, The Netherlands) 
Biopsy available from 100 patients
Gender
Male
Female
N=112
Tumor profiling
N=100
No mutation
KRAS
FGFR1
AGFR
BRAF
Other
Histology
Adenocarcinoma
Squamous cell 
carcinoma
Carcinosarcoma
N=113
Therapy
Nivolumab
Pembrolizumab
Atezolizumab
N=113 Ipilimumab/
nivolumab
PD-L1 expression
N=65
0 %
1-50 %
>50 %
Response
CR
PR
SD
N=113 PD
NE
